Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2011 by North Jersey Endocrine Consultants, LLC.
Recruitment status was  Active, not recruiting
Amylin Pharmaceuticals, LLC.
Information provided by (Responsible Party):
Cheryl Rosenfeld, DO, North Jersey Endocrine Consultants, LLC Identifier:
First received: June 3, 2010
Last updated: October 13, 2011
Last verified: October 2011
No Study Results Posted on for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: April 2012
  Estimated Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)